Skip to main content

EMBL Becomes Customer of Amersham s CodeLink Microarray Platform

This update serves to clarify that Amersham has not sold its CodeLink business to EMBL, but rather a CodeLink system for internal research.


NEW YORK, Jan. 21 (GenomeWeb News) - Amersham Biosciences has sold a CodeLink microarray platform to the European Molecular Biology Laboratory, Amersham said today.


EMBL's genomics core facility in Heidelberg will offer gene-expression services based on the technology to EMBL groups and their collaborators. In addition, EMBL and Amersham will jointly organize training and access to the platform. An EMBL developmental biology research groups has already been using CodeLink microarrays to study gene expression in mice, according to Amersham.


According to the EMBL website, its core facility is also offering services using Affymetrix's gene expression platform.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.